CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SNOY | 9.30 | 0.14 | +1.53% |
| YieldMax SNOW Option Income Strategy ETF (SNOY) | |||
| EZJ | 59.91 | N/A | N/A |
| ProShares Ultra MSCI Japan (EZJ) | |||
| XLRE | 44.58 | -0.06 | -0.13% |
| State Street Real Estate Select Sector SPDR ETF (XLRE) | |||
| BSL | 12.90 | -0.02 | -0.15% |
| Blackstone Senior Floating Rate 2027 Term Fund | |||
| FIIG | 20.01 | -0.14 | -0.69% |
| First Trust Intermediate Duration Investment Grade Corporate ETF (FIIG) | |||
A.I.dvisor indicates that over the last year, CGON has been loosely correlated with MLTX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CGON jumps, then MLTX could also see price increases.
| Ticker / NAME | Correlation To CGON | 1D Price Change % | ||
|---|---|---|---|---|
| CGON | 100% | -2.81% | ||
| MLTX - CGON | 49% Loosely correlated | -0.48% | ||
| ORKA - CGON | 44% Loosely correlated | +4.72% | ||
| SRRK - CGON | 43% Loosely correlated | -6.89% | ||
| IDYA - CGON | 43% Loosely correlated | -0.87% | ||
| LXEO - CGON | 40% Loosely correlated | -2.55% | ||
More | ||||
Industry Biotechnology
CGON moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 29 of 30 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on CGON as a result. In 37 of 49 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for CGON just turned positive on October 22, 2026. Looking at past instances where CGON's MACD turned positive, the stock continued to rise in 26 of 29 cases over the following month. The odds of a continued upward trend are 90%.
Following a +9.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGON advanced for three days, in 118 of 148 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The 10-day RSI Indicator for CGON moved out of overbought territory on November 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 similar instances where the indicator moved out of overbought territory. In 11 of the 16 cases, the stock moved lower in the following days. This puts the odds of a move lower at 69%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
CGON broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CGON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.545) is normal, around the industry mean (3.498). P/E Ratio (-28.249) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. CGON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.